FindTrial
Sign In

Efficacy and prediction analysis of pegylated interferon a-2b in the treatment of HBeAg negative chronic hepatitis B patients with normal ALT

Efficacy and prediction analysis of pegylated interferon a-2b in the treatment of HBeAg negative chronic hepatitis B patients with normal ALT

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300075338
Enrollment
Unknown
Registered
2023-09-01
Start date
2021-03-02
Completion date
Unknown
Last updated
2023-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis B

Interventions

Interferon treatment group:PegIFN application to patients in the interferon treatment group a- 2b injection 180 µ G subcutaneous injection once a week, based on the HBV DNA and HBsAg response after 24
Tenofovir treatment group:Continuous application of TFV therapy

Sponsors

Shengjing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Age 18-55 2. HBsAg positive for more than 6 months 3. HBeAg negative, HBV DNA>20 IU/ml 4. ALT=40 IU/ml 5. Initial treatment

Exclusion criteria

Exclusion criteria: 1. Liver cirrhosis or liver cancer 2. Merge with other diseases 3. Contraindications to the use of interferon

Design outcomes

Primary

MeasureTime frame
Virology and serological response rates (HBV DNA negative conversion rate, HBsAg negative conversion rate, and serum conversion rate) during follow-up and at the end of treatment;—

Secondary

MeasureTime frame
Prediction of HBsAg levels at 24 weeks of treatment and efficacy at 48 and 96 weeks of treatment;—

Countries

China

Contacts

Public ContactDou Xiaoguang

Shengjing Hospital of China Medical University

guang40@163.com+86 189 4025 1121

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026